Long-term follow-up data from the phase III KATHERINE study in people with HER2-positive early-stage breast cancer who have residual invasive disease following neoadjuvant treatment showed that a statistically significant and clinically meaningful improvement in overall survival, a secondary endpoint, was observed with adjuvant Kadcyla (ado-trastuzumab emtansine) compared to Herceptin (trastuzumab).
Further positive results from the phase III SERENA-6 trial showed camizestrant plus a cyclin-dependent kinase 4/6 inhibitor—palbociclib, ribociclib or abemaciclib—maintained its progression-free survival benefit with longer follow-up and delivered a statistically significant and clinically meaningful improvement in second progression-free survival, demonstrating sustained benefit beyond initial treatment.
